211 related articles for article (PubMed ID: 27633411)
1. Third-Line Treatment Options for Kidney Cancer.
Posadas EM; Limvorasak S; Figlin RA
Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
[No Abstract] [Full Text] [Related]
2. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
3. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
4. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
5. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
7. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
Elsada A; Adler AI
Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
[No Abstract] [Full Text] [Related]
8. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
9. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
10. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
12. Sequencing systemic therapies in advanced RCC: is there a best strategy?
Powles T; Crusz SM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714492
[TBL] [Abstract][Full Text] [Related]
13. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
[No Abstract] [Full Text] [Related]
14. [ASCO 2006: temsirolimus increases survival].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
[No Abstract] [Full Text] [Related]
15. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
16. [Drug now immediately available in Germany].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
[No Abstract] [Full Text] [Related]
17. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
18. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
Hahn AW; Agarwal N
Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
[No Abstract] [Full Text] [Related]
19. [Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy].
Störkel S
Pathologe; 2010 Feb; 31(1):50-3. PubMed ID: 20084384
[TBL] [Abstract][Full Text] [Related]
20. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
